股市必读：博瑞医药（688166）12月30日主力资金净流出2058.75万元，占总成交额10.03%

Core Viewpoint - The company, Borui Pharmaceutical, reported a stock price of 49.4 yuan as of December 30, 2025, with a slight decline of 0.66% and a trading volume of 41,400 shares, amounting to a total transaction value of 205 million yuan [1]. Trading Information Summary - On December 30, the main funds experienced a net outflow of 20.59 million yuan, accounting for 10.03% of the total transaction value; retail investors saw a net inflow of 12.39 million yuan, representing 6.04% of the total [2]. - The company’s stock trading saw a turnover rate of 0.98% [1]. Company Announcements Summary - The underwriting and sponsoring company, Guolian Minsheng Securities, conducted an on-site inspection of Borui Pharmaceutical for its 2025 annual continuous supervision work, confirming that the company has a sound governance structure and complies with regulations regarding fundraising and investment [2]. - The board of directors approved a proposal to postpone the expected operational status date for several fundraising projects to March 2027, due to pending product approvals and the need for additional construction of an automated warehouse [2][3]. Internal Governance and Audit - Borui Pharmaceutical established an internal audit management system to ensure independent auditing of internal controls, financial information, and operational activities, with regular reporting to the audit committee [4]. - The company also implemented a foreign exchange trading management system to mitigate exchange rate risks and ensure the safety of funds, prohibiting speculative activities [5]. Fundraising Management - The company has set up a fundraising management method to regulate the storage, use, and supervision of raised funds, ensuring they are used exclusively for designated projects and not for financial investments [6]. - Any changes in fundraising projects or surplus fund usage must go through board or shareholder meeting approval, with biannual progress checks and annual verification reports from accounting firms [6]. Shareholding Management - Borui Pharmaceutical has established a management system for shares held by directors and senior management, outlining restrictions on share transfers and trading periods, as well as disclosure requirements [7].